High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
Open Access
- 3 March 2004
- Vol. 100 (8), 1724-1733
- https://doi.org/10.1002/cncr.20152
Abstract
BACKGROUND High‐dose methotrexate (HDMTX) is used frequently in combination regimens that include nephrotoxic chemotherapy. The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome. METHODS The authors evaluated MTX pharmacokinetics in 140 patients who were treated with 1083 courses of HDMTX on 3 consecutive studies of multiagent chemotherapy at a single institution. The influence of MTX pharmacokinetics on the outcome of 107 patients with localized disease was examined. RESULTS Mean peak MTX concentrations ≥ 1000 μM were achieved in 135 patients (96%). MTX clearance was decreased after cisplatin therapy (P = 0.01), after cisplatin in combination with ifosfamide therapy (P < 0.0001), and after MTX therapy (P = 0.003). In patients with localized osteosarcoma, a higher mean MTX area under the curve, a higher mean peak concentration of MTX, a longer mean time above a threshold concentration (500 μM), and a lower mean MTX clearance were associated with lower probability of event‐free survival (EFS). Patients who had a mean peak MTX plasma concentration > 1500 μM were found to have a worse outcome (estimated 5‐year EFS, 58.5% ± 6.7%) compared with patients who had a mean peak concentration ≤ 1500 μM (estimated 5‐year EFS, 75.5% ± 6.6%; P = 0.02). CONCLUSIONS When HDMTX (12 g/m2) was used with multiagent therapy for patients with osteosarcoma, very high MTX exposures were associated with poorer outcome. The prospective evaluation of MTX pharmacokinetics and their relation to outcome in a large study is warranted to further substantiate the current findings and to elucidate the causative mechanism. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 41 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th StudyActa Oncologica, 1998
- Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experienceCancer, 1992
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityThe New England Journal of Medicine, 1986
- Alternative Approaches to Estimation of Population Pharmacokinetic Parameters: Comparison with the Nonlinear Mixed-Effect ModelDrug Metabolism Reviews, 1984
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityThe New England Journal of Medicine, 1977
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958